{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-033014","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.344651+00:00","generated_at":"2026-06-10T08:32:33.191337+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cardiff Oncology reports positive Phase 2 data for onvansertib in pancreatic and lung cancers","bullets":["mPDAC Phase 2: ORR 19% (1 confirmed PR, 3 pending) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo.","Biomarker trial: single-agent onvansertib reduced Ki67 by 86% and CA19-9 by 28% in refractory mPDAC.","Plans first-line mPDAC investigator-initiated trial of onvansertib + Gemzar/Abraxane at OHSU.","SCLC Phase 2: preliminary single-agent activity; safety confirmed; trial continues enrolling.","Conference call scheduled for Sept 26, 2023 at 5pm ET to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-033014","json":"https://secwatch.observer/filing/0001628280-23-033014.json","markdown":"https://secwatch.observer/filing/0001628280-23-033014.md","text":"https://secwatch.observer/filing/0001628280-23-033014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/0001628280-23-033014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023033014/crdf-20230926.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:32:33.191337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}